Valuation: Design Therapeutics, Inc.

Market Cap 732M 654M 610M 554M 1.04B 70.77B 1.05B 7.33B 2.86B 35.99B 2.75B 2.69B 116B P/E 2026 *
-8.66x
P/E 2027 * -7.17x
Enterprise Value 755M 675M 630M 572M 1.08B 73.07B 1.09B 7.57B 2.96B 37.16B 2.84B 2.77B 119B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.13%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Design Therapeutics, Inc.

1 day-2.34%
1 week-7.00%
Current month-7.00%
1 month-22.79%
3 months-20.53%
6 months-4.34%
Current year+24.63%
1 week 11.58
Extreme 11.575
12.94
1 month 11.58
Extreme 11.575
15.49
Current year 8.23
Extreme 8.23
17.25
1 year 5.28
Extreme 5.28
17.25
3 years 1.96
Extreme 1.96
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 2023-08-24
Chief Tech/Sci/R&D Officer 60 2025-04-16
Chief Tech/Sci/R&D Officer - 2025-01-31
Director TitleAgeSince
Chairman 56 2017-12-17
Director/Board Member 71 2019-06-30
Director/Board Member 49 2020-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
3/31/26 Free

Director

67,500 0.1185%
1/2/26 Free

Chief Executive Officer

750,000 1.3166%
1/2/26 Free

Director

45,000 0.0790%
Change 5-day change 1-year change 3-year change Capi.($)
-2.34%-7.00%+80.12%+408.26% 749M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.34% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
+0.50%-2.14%+331.33%+702.20% 42.84B
-0.72%-3.99%+28.50%+29.94% 42.79B
+0.34%-0.52%+6.56%+109.35% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-0.50%-3.10%-10.19%-14.35% 24.05B
-3.32%-10.86%-37.32%+316.28% 22.98B
Average -0.14%-2.83%+48.79%+181.24% 38.77B
Weighted average by Cap. +0.66%-1.81%+52.43%+149.88%

Financials

2026 *2027 *
Net sales - -
Net income -84.9M -75.85M -70.77M -64.28M -121M -8.21B -122M -850M -332M -4.18B -319M -312M -13.43B -115M -103M -96.1M -87.29M -164M -11.15B -166M -1.15B -451M -5.67B -433M -423M -18.23B
Net Debt 23.81M 21.28M 19.85M 18.03M 33.96M 2.3B 34.21M 239M 93.19M 1.17B 89.4M 87.46M 3.77B -295M -264M -246M -223M -421M -28.55B -424M -2.96B -1.15B -14.52B -1.11B -1.08B -46.67B
Projected Income Statement - Annual - Design Therapeutics, Inc.
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
55
Date Price Change Volume
26-10-07 US$11.69 -2.34% 344,454
26-10-06 US$11.97 -3.62% 642,530
26-10-05 US$12.42 +0.65% 680,775
26-10-02 US$12.34 +0.82% 565,845
26-10-01 US$12.24 -2.63% 346,590
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Design Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.69USD
Average target price
21.71USD
Spread / Average Target
+85.75%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Design Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. DSGN Stock